Cargando…

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial

OBJECTIVE: To evaluate radiographic progression in patients with ankylosing spondylitis (AS) receiving two different doses of the tumour necrosis factor antagonist golimumab. METHODS: 356 patients with AS were randomly assigned to placebo, or golimumab 50 mg or 100 mg every 4 weeks (wks). At wk16, p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Braun, Jürgen, Baraliakos, Xenofon, Hermann, Kay-Geert A, Deodhar, Atul, van der Heijde, Désirée, Inman, Robert, Beutler, Anna, Zhou, Yiying, Xu, Stephen, Hsu, Benjamin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2014
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033110/ https://www.ncbi.nlm.nih.gov/pubmed/23644549 http://dx.doi.org/10.1136/annrheumdis-2012-203075

Ejemplares similares

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
por: Inman, Robert D., et al.
Publicado: (2016)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study
por: Baraliakos, Xenofon, et al.
Publicado: (2023)

Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients
por: Maksymowych, Walter P, et al.
Publicado: (2018)

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study
por: Deodhar, Atul A., et al.
Publicado: (2022)

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
por: Molnar, Christoph, et al.
Publicado: (2018)

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2017)

Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies
por: Braun, Jürgen, et al.
Publicado: (2018)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
por: Visvanathan, S, et al.
Publicado: (2008)

Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
por: Ramiro, Sofia, et al.
Publicado: (2013)

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
por: Deodhar, Atul, et al.
Publicado: (2021)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
por: Lee, Jeong Seok, et al.
Publicado: (2018)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
por: Borse, Rebekah H., et al.
Publicado: (2017)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
por: van der Heijde, Désirée, et al.
Publicado: (2018)

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
por: Heslinga, SC, et al.
Publicado: (2018)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Effect of Upadacitinib on Disease Activity, Pain, Fatigue, Function, Health-Related Quality of Life and Work Productivity for Biologic Refractory Ankylosing Spondylitis
por: Navarro-Compán, Victoria, et al.
Publicado: (2023)

What do we know about co-stimulatory and co-inhibitory immune checkpoint signals in ankylosing spondylitis?
por: Schütz, Christian, et al.
Publicado: (2023)

Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3fpr36ht9qncg5d0ga831s57ub